Prof. Chiara Cremolini reviews the latest clinical and real-world data in the treatment of BRAF-mutant and MSI-H colorectal cancer (CRC), with a particular focus on the following two studies:
- BREAKWATER: First-line encorafenib + cetuximab + mFOLFOX6 vs standard of care in BRAFV600E-mutant mCRC
- CheckMate 8HW: Nivolumab + ipilimumab vs chemotherapy or nivolumab monotherapy for MSI-H/dMMR mCRC
Watch the short video for a summary of Professor Cremolini’s perspectives. Download the slide deck for more details on the data.